Chifumi Imai

Chifumi Imai is a prominent inventor based in Shizuoka, Japan. She has made significant contributions to the field of biochemistry, particularly in the development of antibody-containing preparations. With a total of 3 patents to her name, her work focuses on enhancing the stability and efficacy of bispecific antibodies.

Latest Patents

One of her latest patents involves an antibody-containing preparation that relates to stable solution formulations. This invention specifically addresses the suppression of aggregate formation of Emicizumab (ACE910), a bispecific antibody that functionally substitutes for FVIII. The formulation is designed to maintain a pH range of 4.5 to 6.5 and includes specific concentrations of histidine-aspartate buffer, Poloxamer 188, and arginine. Another notable patent details methods of treatment that utilize various bispecific antibodies, which bind to blood coagulation factors IX and X, effectively substituting for the cofactor function of blood coagulation factor VIII.

Career Highlights

Chifumi Imai is currently employed at Chugai Seiyaku Kabushiki Kaisha, where she continues to innovate in the field of antibody research. Her work has been instrumental in advancing therapeutic options for patients requiring blood coagulation treatments.

Collaborations

Throughout her career, Imai has collaborated with notable colleagues, including Tomoyuki Igawa and Zenjiro Sampei. These partnerships have fostered a collaborative environment that enhances the research and development of new biopharmaceuticals.

Conclusion

Chifumi Imai's contributions to the field of antibody solutions exemplify her dedication to innovation in biochemistry. Her patents reflect a commitment to improving therapeutic options for patients, showcasing her role as a leading inventor in this vital area of research.

This text is generated by artificial intelligence and may not be accurate.